CDK5 and Alzheimer disease: Consequently, regulation of Prx1 may be a potential inhibitor of STZ-induced neurodegeneration by preventing the Ca2+/capain-2/Cdk5 signal pathway and may be considered as a possible strategy for developing therapies to treat the pathogenesis of AD.